XML 57 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information (Tables)
 9 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Reconciliation of Earnings/(Loss) from Continuing Operations to EBITDA
(Dollars in millions)Three Months Ended  
March 31,		Nine Months Ended  
March 31,
2024202320242023
Segment EBITDA reconciled to net (loss) earnings:
Biologics$49 $6 $136 $299 
Pharma and Consumer Health153 125 380 368 
Sub-Total$202 $131 $516 $667 
Reconciling items to net earnings
Unallocated costs (1)
(97)(256)(1,033)(394)
Depreciation and amortization(126)(106)(359)(308)
Interest expense, net(65)(51)(189)(130)
Income tax (expense) benefit(15)55 (1)19 
Net loss$(101)$(227)$(1,066)$(146)
(1) Unallocated costs include restructuring and special items, stock-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:                                                        
(Dollars in millions)Three Months Ended  
March 31,
Nine Months Ended  
March 31,
2024202320242023
Impairment charges and gain/loss on sale of assets(a)
$(13)$(6)$(27)$(4)
Stock-based compensation (17)(6)(52)(35)
Restructuring and other special items(b)
(20)(17)(126)(59)
Goodwill impairment charges(c)
— (210)(687)(210)
Pension settlement charges(9)— (12)— 
Other (expense) income, net(d)
(4)4 (21)2 
Unallocated corporate costs, net(34)(21)(108)(88)
Total unallocated costs$(97)$(256)$(1,033)$(394)

(a)    Impairment charges and gain/loss on sale of assets for the three and nine months ended March 31, 2024 includes right-of-use asset impairment charges associated with under utilized facilities in our Biologics segment.    
Impairment charges and gain/loss on sale of assets for the three and nine months ended March 31, 2024 includes fixed asset impairment charges associated with equipment for a product with significant decline in demand in the Company's Biologics segment.
(b)    Restructuring and other special items during the three and nine months ended March 31, 2024 include restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization. For further details on restructuring charges, see Note 8, Restructuring Costs to the Consolidated Financial Statements.
Restructuring and other special items during the three months ended March 31, 2023 include (i) restructuring charges associated with plans to reduce costs, consolidate facilities, and optimize our infrastructure across the organization and (ii) transaction and integration costs associated with the Metrics acquisition. Restructuring and other special items for the nine months ended March 31, 2023 also includes warehouse exit costs for a product the Company no longer manufactures in its Pharma and Consumer Health segment. For further details on restructuring charges, see Note 8, Restructuring Costs to the Consolidated Financial Statements.
(c)    Goodwill impairment charges during the nine months ended March 31, 2024 were associated with the Company's Consumer Health and Biomodalities reporting units, which are part of the Company's Pharma and Consumer Health and Biologics segments, respectively. For further details, see Note 4, Goodwill to the Consolidated Financial Statements.
Goodwill impairment charges during the three and nine months ended March 31, 2023 was associated with the Company’s Consumer Health reporting unit. For further details, see Note 4, Goodwill.
(d)    Other expense, net during the three and nine months ended March 31, 2024 and 2023 primarily includes foreign currency remeasurement losses/gains.
Total Assets for Each Segment and Reconciling in Consolidated Financial Statements
The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements.
(Dollars in millions)March 31,
2024		June 30,
2023
Assets:
Biologics$5,263 $5,746 
Pharma and Consumer Health4,588 4,867 
Corporate and eliminations28 164 
Total assets$9,879 $10,777